A study by researchers at Yale Cancer Center demonstrated that enfortumab vedotin significantly prolonged survival as compared with standard chemotherapy in patients with locally advanced or metastatic urothelial carcinoma or bladder cancer, who had previously received platinum-based treatment and a PD-1–PD-L1 inhibitor.
FDA has cleared the first at-home self-collection kit for HPV screening, removing significant obstacles to cervical cancer detection.
